Literature DB >> 15687596

Development of herceptin.

P Carter1, B M Fendly, G D Lewis, M X Sliwkowski.   

Abstract

Year:  2000        PMID： 15687596     DOI： 10.3233/bd-1999-11109

Source DB:  PubMed          Journal:  Breast Dis        ISSN： 0888-6008


× No keyword cloud information.
  7 in total

1.  Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach.

Authors:  Andreas Lehmann; Josephine H F Wixted; Maxim V Shapovalov; Heinrich Roder; Roland L Dunbrack; Matthew K Robinson
Journal:  MAbs       Date:  2015-09-04       Impact factor: 5.857

2.  Crystallization and preliminary crystallographic studies of the single-chain variable fragment of antibody chA21 in complex with an N-terminal fragment of ErbB2.

Authors:  Yang Liu; Huihao Zhou; Juanjuan Zhu; Yongxiang Gao; Liwen Niu; Jing Liu; Maikun Teng
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-06-27

3.  Molecular modeling of nearly full-length ErbB2 receptor.

Authors:  Péter Bagossi; Gábor Horváth; György Vereb; János Szöllösi; József Tözsér
Journal:  Biophys J       Date:  2004-12-13       Impact factor: 4.033

4.  Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging.

Authors:  Jennifer L Macdonald-Obermann; Sangeeta Adak; Ralf Landgraf; David Piwnica-Worms; Linda J Pike
Journal:  J Biol Chem       Date:  2013-09-06       Impact factor: 5.157

5.  Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr701 phosphorylation.

Authors:  Marco Gaviraghi; Andrea Rabellino; Annapaola Andolfo; Matthias Brand; Chiara Brombin; Paola Bagnato; Giuseppina De Feudis; Andrea Raimondi; Alberta Locatelli; Daniela Tosoni; Davide Mazza; Luca Gianni; Giovanni Tonon; Yosef Yarden; Carlo Tacchetti; Tiziana Daniele
Journal:  Sci Rep       Date:  2020-10-09       Impact factor: 4.379

6.  Reorienting the Fab domains of trastuzumab results in potent HER2 activators.

Authors:  Justin M Scheer; Wendy Sandoval; J Michael Elliott; Lily Shao; Elizabeth Luis; Sock-Cheng Lewin-Koh; Gabriele Schaefer; Richard Vandlen
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

7.  Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples.

Authors:  George Vasmatzis; Xue Wang; James B Smadbeck; Stephen J Murphy; Katherine B Geiersbach; Sarah H Johnson; Athanasios G Gaitatzes; Yan W Asmann; Farhad Kosari; Mitesh J Borad; Daniel J Serie; Sarah A McLaughlin; Jennifer M Kachergus; Brian M Necela; E Aubrey Thompson
Journal:  BMC Cancer       Date:  2018-07-13       Impact factor: 4.430
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.